FDA approves lenalidomide for follicular and marginal zone lymphoma

On May 28 2019 the Food and Drug Administration approved lenalidomide REVLIMID Celgene Corp in combination with a rituximab product for previously treated follicular lymphoma FL and previously treated marginal zone lymphoma MZL The MAGNIFY clinical trial [...]